Drugs in Treating Urinary Schistosomiasis

Urinary schistosomiasis caused by trematodes of the genus Schistosoma known as Schistosoma haematobium. Schistosoma haematobium, also known to be “urinary blood fluke” that inhabits and multiplies eggs in the small venules of the perivesical and portal systems. Urinary schistosomiasis is endemic in 53 countries in Africa and the Middle East. A cholinesterase inhibitor Metrifonate is another selective treatment for SH; it has good efficacy and safety properties. Although it is economic, causes low recurrence rates. Metrifonate is that a prophylactic dose which is needed within two years to guard against recurrence. Niridazole is also highly effective for treating schistosomiasis, and a single dose of niridazole daily has a high cure rate.

  • In vitro studies
  • Albendazole Treatment
  • Egg Reduction Rate

Related Conference of Drugs in Treating Urinary Schistosomiasis

May 03-04, 2021

International Online Conference on Immunology

New York, USA
May 06-06, 2021

3rd International Conference on Dermatology and Allergic Diseases

Singapore City, Singapore
May 06-07, 2021

9th World Summit on immunology & immunotherapy

Prague, Czech Republic
June 23-24, 2021

34th World Congress on Vaccines and Immunization

Osaka, Australia
August 27-28, 2021

5th International Conference on Emerging Infectious Diseases

Amsterdam, Netherlands
October 12-13, 2021

International Conference on Vaccine and Vaccine research

Manila, Philippines
October 14-15, 2021

13th Annual Conference on Clinical Immunology

Cape Town, South Africa
October 14-15, 2021

11th International Conference on Bacteriology and Infectious Diseases

Cape Town, South Africa
November 10-11, 2021

International Conference on Immunology Research

New York, USA

Drugs in Treating Urinary Schistosomiasis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in